Hancock, D B
Reginsson, G W
Gaddis, N C
Chen, X
Saccone, N L
Lutz, S M
Qaiser, B
Sherva, R
Steinberg, S
Zink, F
Stacey, S N
Glasheen, C
Chen, J
Gu, F
Frederiksen, B N
Loukola, A
Gudbjartsson, D F
Brüske, I
Landi, M T
Bickeböller, H
Madden, P
Farrer, L
Kaprio, J
Kranzler, H R
Gelernter, J
Baker, T B
Kraft, P
Amos, C I
Caporaso, N E
Hokanson, J E
Bierut, L J
Thorgeirsson, T E
Johnson, E O
Stefansson, K
Article History
Received: 26 June 2015
Accepted: 19 August 2015
First Online: 6 October 2015
Competing interests
: LJB and the spouse of NLS are listed as inventors on U.S. Patent 8080371, ‘Markers for Addiction’ covering the use of certain SNPs in determining the diagnosis, prognosis and treatment of addiction. GWR, SS, FZ, SNS, DFG, TET, and KS are employees of deCODE Genetics/Amgen. Although unrelated to this research, HRK has been a consultant or advisory board member for Alkermes, Lilly, Lundbeck, Otsuka and Pfizer and is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, supported by AbbVie, Ethypharm, Lilly, Lundbeck and Pfizer. JK consulted for Pfizer from 2012 to 2014 on nicotine dependence. The remaining authors declare no conflict of interest.